At JAX, we live and breathe continuous innovation, from developing new solutions to hosting events sharing the latest research and cutting-edge industry knowledge.
Settings
Save and close
At JAX, we live and breathe continuous innovation, from developing new solutions to hosting events sharing the latest research and cutting-edge industry knowledge.
In partnership with the iPSC Neurodegenerative Disease Initiative, a project from the Center for Alzheimer’s and Related Dementias (NIH), and with support from the Chan Zuckerberg Initiative, and Aligning Science Across Parkinson's (ASAP), The Jackson Laboratory now offers a catalog of human induced pluripotent stem cells (iPSCs) for Alzheimer’s and Related Dementias (ADRDs), ALS, and other neurodegenerative disorders.
View more
JAX Cytokine Release Syndrome (CRS) Evaluation Studies are built on humanized platforms to provide the most translationally relevant data to assess antitumor antibodies which may induce CRS and immunosuppressive antibodies for the prevention or resolution of CRS.
View more
The HSA-LR20b model of Myotonic Dystrophy (DM) (JR 32031), whose natural history has been documented by the experts at JAX, exhibits myotonia and mRNA splicing abnormalities at a younger age than thought, displays hallmark DM muscle histopathology and quantifiable mechanical dystonia. Importation and characterization of this model was supported by Myotonic Dystrophy Foundation. This model, in combination with the assays standardized and validated at JAX, are core features of the new DM drug testing facility and help you de-risk your preclinical drug studies.
JAX has the most comprehensive portfolio of MASH (formerly called non-alcoholic steatohepatitis, or NASH) mouse models to support your preclinical research needs. Leverage both traditional and novel MASH models to test your unique research questions, and gain confidence in your study results by utilizing the models that are right for you.
View more
Cancer cells have found ingenious ways to evade the body’s immune system. These cells can shut off cytotoxic activity of anti-tumor T-cells, promoting their own survival. Immunotherapeutic approaches, by design, overcome these tumor mediated inhibitory mechanisms, allowing the patient’s immune system to thwart the invading tumor.
View more